Anaphylactic reaction to ferric carboxymaltose: A case series
DOI:
https://doi.org/10.53411/jpadr.2022.3.4.7Keywords:
Iron deficiency anemia, ferric carboxymaltose, hypersensitivity, anaphylaxisAbstract
Introduction: Intravenous iron is widely used for the treatment of iron deficiency anemia when oral iron is inappropriate, ineffective, or poorly tolerated. Acute hypersensitivity reactions during iron infusions are very rare but can be life-threatening.
Case Reports: We report herein two cases, the first being a case of severe anaphylactic reaction amounting to anaphylactic shock and the second case presenting with an anaphylactic reaction, both with IV Ferric carboxymaltose(FCM) in pregnant women suffering from Iron Deficiency Anemia(IDA).
Conclusion: A public health initiative aimed at reducing the number of severe adverse reactions to parenteral iron would require a rational use of this drug.
References
Bashiri, A., Burstein, E., Sheiner, E., & Mazor, M. (2003). Anemia during pregnancy and treatment with intravenous iron: review of the literature. European journal of obstetrics, gynecology, and reproductive biology, 110(1), 2–7.
Brown S. G. (2004). Clinical features and severity grading of anaphylaxis. The Journal of allergy and clinical immunology, 114(2), 371–376.
EMA-CHMP. (2013). Assessment report for: iron containing intravenous (IV) medicinal products EMA/549569/2013. Retrieved from: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals-document/IV_iron_31/WC500150771.pdf .
European Medicines Agency. New recommendations to manage risk of allergic reactions with intravenous iron-containing medicines. European Medicines Agency 2013. EMA/579491/2013:1–3 Retrieved from: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/IV_iron_31/WC500151308.pdf
FDA-CDER. (2020). Injectafer (VIT-45, ferric carboxymaltose injection;FCM) for the treatment of iron deficiency anemia. Updated clinical safety information. Retrieved from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203565Orig1s000MedR.pdf
Ferinject (ferric carboxymaltose) Uptating 13 November 2019. Retrieved from: https://www.medicines.org.uk/emc/product/5910/smpc .
Freter, S., Davidman, M., Lipman, M., & Bercovitch, D. (1997). Pulmonary edema: atypical anaphylactoid reaction to intravenous iron dextran. American journal of nephrology, 17(5), 477–479.
Mulder, M. B., van den Hoek, H. L., Birnie, E., van Tilburg, A. J. P., & Westerman, E. M. (2019). Comparison of hypersensitivity reactions of intravenous iron: iron isomaltoside-1000 (Monofer® ) versus ferric carboxy-maltose (Ferinject® ). A single center, cohort study. British journal of clinical pharmacology, 85(2), 385–392.
Pavord, S., Myers, B., Robinson, S., Allard, S., Strong, J., Oppenheimer, C., & British Committee for Standards in Haematology (2012). UK guidelines on the management of iron deficiency in pregnancy. British journal of haematology, 156(5), 588–600.
Reveiz, L., Gyte, G. M., Cuervo, L. G., & Casasbuenas, A. (2011). Treatments for iron-deficiency anaemia in pregnancy. The Cochrane database of systematic reviews, (10), CD003094.
Ring, J., Grosber, M., Möhrenschlager, M., & Brockow, K. (2010). Anaphylaxis: acute treatment and management. Chemical immunology and allergy, 95, 201–210.
Scott L. J. (2018). Ferric Carboxymaltose: A Review in Iron Deficiency. Drugs, 78(4), 479–493.
WHO. Iron-deficiency anemia; Assessment, Prevention and Control; A guide for programme managers. Geneva: World Health Organization; 2001. United Nations Children's Fund UNU.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Parth Kanani, Sushma Shah, Supriya Malhotra
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
